BUZZ-Aralez Pharmaceuticals Inc: Jumps as FDA approves treatment

Thu Sep 15, 2016 10:53am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian specialty pharmaceutical's U.S.-listed shares up about 10 pct at $6

** Toronto-traded shares up 11 pct at C$7.97

** Aralez says U.S. FDA approves its once-daily treatment, Yosprala, in patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular side-effects, and who are at risk of developing aspirin-associated gastric ulcers

** Aspirin is the standard-of-care for the secondary cardiovascular event prevention but gastrointestinal symptoms are often cited as the reason patients discontinue treatment; Up to 26.2 million adults in U.S. are at risk for secondary cardiovascular events

** Aralez says it is expanding its sales force by 85 representatives, and expects to launch the treatment in U.S in October

** Up to Wednesday's close, Aralez's U.S.-listed stock had fallen about 20 pct this year